The company's strategic goal is not a cure but to slow the underlying progression of Parkinson's. By reducing toxic lipids and protecting neurons, the aim is to decelerate the disease's advancement so significantly that patients can effectively outlive its most severe impacts. This reframes the value proposition for a neurodegenerative disease.
Instead of focusing on symptomatic relief, Gain Therapeutics' molecule corrects a misfolded enzyme. This restores the enzyme's ability to break down toxic lipids that accumulate in nerve cells, addressing a root cause of cell damage and disease progression, rather than just managing symptoms like dopamine loss.
Unusually for a Phase 1 safety trial, Gain Therapeutics measured lipid levels in patients' cerebrospinal fluid. They observed a decrease in the target toxic lipids, providing strong, early biological evidence that the drug reaches the brain and works as intended. This de-risks future development by establishing a clear biomarker of effect.
While designed for the 10% of Parkinson's patients with a specific genetic variant, Gain Therapeutics' trial data shows its drug may benefit a larger group. About 50% of patients without the gene defect also have the toxic lipid buildup the drug targets, suggesting a significantly expanded potential market beyond the initial niche population.